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Abstract
Background:  Bloodstream infections are associated with significant patient morbidity and
mortality. Antimicrobial susceptibility patterns should guide the choice of empiric antimicrobial
regimens for patients with bacteremia.
Methods: From January to December of 2002, 82,569 bacterial blood culture isolates were
reported to The Surveillance Network (TSN) Database-USA by 268 laboratories. Susceptibility to
relevant antibiotic compounds was analyzed using National Committee for Clinical Laboratory
Standards guidelines.
Results: Coagulase-negative staphylococci (42.0%), Staphylococcus aureus (16.5%), Enterococcus
faecalis (8.3%), Escherichia coli (7.2%), Klebsiella pneumoniae (3.6%), and Enterococcus faecium (3.5%)
were the most frequently isolated bacteria from blood cultures, collectively accounting for >80%
of isolates. In vitro susceptibility to expanded-spectrum β-lactams such as ceftriaxone were high
for oxacillin-susceptible coagulase-negative staphylococci (98.7%), oxacillin-susceptible S. aureus
(99.8%),  E. coli (97.3%),  K. pneumoniae (93.3%), and Streptococcus pneumoniae (97.2%).
Susceptibilities to fluoroquinolones were variable for K. pneumoniae (90.3–91.4%), E. coli (86.0–
86.7%), oxacillin-susceptible S. aureus (84.0–89.4%), oxacillin-susceptible coagulase-negative
staphylococci (72.7–82.7%), E. faecalis (52.1%), and E. faecium (11.3%). Combinations of
antimicrobials are often prescribed as empiric therapy for bacteremia. Susceptibilities of all blood
culture isolates to one or both agents in combinations of ceftriaxone, ceftazdime, cefepime,
piperacillin-tazobactam or ciprofloxacin plus gentamicin were consistent (range, 74.8–76.3%) but
lower than similar β-lactam or ciprofloxacin combinations with vancomycin (range, 93.5–96.6%).
Conclusion:  Ongoing surveillance for antimicrobial susceptibility remains essential, and will
enhance efforts to identify resistance and attempt to limit its spread.
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Background
Bloodstream infections cause significant morbidity and
mortality worldwide and are among the most common
healthcare-associated infections [1-6]. It is estimated that
2 million patients per year in the United States acquire
infections while in hospitals, approximately 350,000
(10–20%) of these infections involve the bloodstream,
and 90,000 (4.5%) are fatal [1,6,7]. Advances in medi-
cine, efforts to control medical costs, and incentives for
outpatient care have resulted in an increasingly concen-
trated population of seriously ill patients in hospitals. The
incidence of bloodstream infections in patients treated in
United States hospitals has been reported to correlate with
increasing use of central venous catheters, patient illness
(e.g., oncology, burn/trauma, and high-risk nursery), and
other predisposing factors, including microorganism,
intensive-care unit (ICU) stay, hand washing practices of
medical staff, and adherence to infection control practices
[1,5,6,8]. Respiratory, genitourinary tract, and intra-
abdominal foci are often identifiable sources of blood-
stream infections [9]. Bacteremia due to Enterobacteriaceae
other than Escherichia coli are associated with increased
mortality compared with bloodstream infections due to
Gram-positive species [5]. Gram-negative and polymicro-
bial bacteremia can result in septic shock and mortality is
greater with high-grade bacteremia and polymicrobial
infection [4,5,10]. Efforts need to be extended to prevent
and control serious hospital-acquired infections.
The National Nosocomial Infections Surveillance (NNIS)
system reported that from 1986 to 1997, coagulase-nega-
tive staphylococci and Staphylococcus aureus were the most
common organisms isolated from blood cultures of inten-
sive-care unit (ICU) patients, followed by Enterococcus
spp., Candida albicans, and Enterobacter spp. [11]. How-
ever, only 50% of all positive blood cultures represent true
bloodstream infection [5]. Importantly, although coagu-
lase-negative staphylococci are the most frequently iso-
lated organism from blood cultures, they are clinically
significant <15% of the time [5]. Coagulase-negative bac-
teremia is often the result of long-term use of indwelling
central and peripheral catheters as well as other prosthetic
devices, the ubiquity of these bacteria as normal skin
flora, and the ability of these relatively avirulent organ-
isms to adhere to the surface of biomaterials [5]. Previous
studies have reported that S. aureus and E. coli are the two
most common, clinically significant causes of blood-
stream infections in patients in the United States and
Europe [4,5,12,13] and that 6–18% of bloodstream infec-
tions are polymicrobial [4,5]. Bacteremia may be transient
or indicative of true systemic infection (i.e., sepsis syn-
drome) with an initial focal source such as the lungs (e.g.,
pneumonia) or the urinary tract [10].
The potential for antimicrobial resistance is one consider-
ation for physicians when selecting a regimen with which
to treat patients. This is particularly important for the
treatment of systemic infections as initial antimicrobial
chemotherapy is almost invariably empiric and must be
based on knowledge of the most frequently isolated etio-
logical agents and their antimicrobial susceptibility pat-
terns. Early initiation of appropriate antimicrobial
treatment is critical in decreasing morbidity and mortality
among patients with bloodstream infections [14]. The
current study reports the prevalence and antimicrobial
susceptibility profiles of blood culture isolates from the
United States using The Surveillance Network (TSN) Data-
base-USA (Focus Technologies, Herndon, VA).
Methods
In the current study, results from the TSN Database-USA
from January 1 to December 31, 2002 were used to esti-
mate the prevalence of specific bacterial species as blood
culture isolates in the United States and to determine rates
of antimicrobial susceptibility for commonly tested
agents among the most prevalent species identified. TSN
assimilated antimicrobial susceptibility testing and
patient demographic data from a network of 268 hospi-
tals in the United States in 2002 [15]. All blood culture
isolates were identified at the participating institutions by
routine methods in use at each laboratory. Antimicrobial
susceptibility testing of patient isolates was conducted
onsite by each participating laboratory as a part of their
routine diagnostic testing. An inpatient isolate was
defined as such by each laboratory participating in TSN.
Data from patients in nursing facilities and hospital out-
patients were excluded from the current analysis.
Laboratories contributing to TSN databases are all nation-
ally-accredited and are invited to participate in TSN based
on factors such as hospital type (e.g., university teaching
hospital, community hospital) and antimicrobial suscep-
tibility testing method used as well as the bed size, patient
population, and geographic location of the hospital(s)
they serve [15]. Only data generated using nationally
approved (Food and Drug Administration-approved) test-
ing methods with MIC results interpreted according to
NCCLS [16] recommendations are included in TSN Data-
base-USA. In addition, a series of quality-control filters
(proprietary critical rule sets) are used to screen suscepti-
bility test results for patterns indicative of testing error;
suspect results are removed from analysis for laboratory
confirmation. TSN reflects current testing in United States
laboratories and is the antimicrobial susceptibility testing
data considered when clinical decisions in participating
institutions are made. The TSN database presumes the evi-
dence of infection, but no clinical correlates are applied
universally. In TSN, any result from the same patient with
the same organism identification and the sameAnnals of Clinical Microbiology and Antimicrobials 2004, 3 http://www.ann-clinmicrob.com/content/3/1/7
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susceptibility pattern received within five days is consid-
ered a repeat culture and is counted only once in the data-
base. In TSN, all isolates are not tested against all agents
and variation can be observed for antimicrobial agents of
the same class such as expanded-spectrum cephalosporins
(ceftriaxone and cefotaxime) and fluoroquinolones (cip-
rofloxacin and levofloxacin) for which similar in vitro
activities have been previously demonstrated.
Results
Table 1 depicts the frequencies of occurrence of the 20
most common bacterial blood culture isolates in the
United States in 2002. A total of 82,569 blood culture iso-
lates were reported to TSN Database-USA in 2002. Coag-
ulase-negative staphylococci accounted for 42.0% of all
isolates. Six organisms, coagulase-negative staphylococci,
Staphylococcus aureus, Enterococcus faecalis, Eschericia coli,
Klebsiella pneumoniae, and Enterococcus faecium accounted
for >80% of all blood culture isolates. Overall frequencies
of isolation were 78.1% gram-positive bacteria and 21.9%
gram-negative bacteria.
Table 2 provides susceptibility rates for commonly tested
antimicrobial agents for the most frequently isolated bac-
terial species in 2002. Greater than 99% of oxacillin-sus-
ceptible  S. aureus isolates and >98% of oxacillin-
susceptible coagulase-negative staphylococci isolates were
susceptible to amoxicillin-clavulanate, cefotaxime, ceftri-
axone, and cefuroxime. Susceptibilities to ciprofloxacin
and levofloxacin, respectively were 88.5% and 89.4% for
oxacillin-susceptible S. aureus and 82.1% and 82.7% for
oxacillin-susceptible coagulase-negative staphylococci.
Among viridans group streptococci, ceftriaxone and cefo-
taxime were equally active based on the susceptibilities of
isolates (89.9% and 89.2%, respectively). S. pneumoniae
susceptibilities to penicillin and trimethoprim-sulfameth-
oxazole were <70% while susceptibilities to levofloxacin,
amoxicillin-clavulanate, and ceftriaxone all exceeded
97%. Greater than 95% of E. faecalis isolates and 33% of
E. faecium isolates from blood were susceptible to
vancomycin.
The oxacillin-resistance rate was 49.3% among blood cul-
ture isolates of S. aureus and 76.7% among blood culture
isolates of coagulase-negative staphylococci (data not
shown). Among oxacillin-resistant coagulase-negative sta-
phylococci and S. aureus, susceptibilities were 32.1–
32.6% (range) and 7.3–7.6% for fluoroquinolones,
respectively, 48.1% and 80.9% for gentamicin, 13.7% and
5.9% for erythromycin, 47.2% and 29.8% for clindamy-
cin, 56.0% and 90.9% for trimethoprim-sulfamethoxa-
zole, and 100% and 100% for vancomycin (data not
shown).
For E. coli, ≥ 97% of isolates were susceptible to amikacin,
cefepime, cefotaxime, ceftriaxone, and nitrofurantoin;
Table 1: Frequencies of occurrence of bacterial species or groups isolated from blood cultures of hospitalized patients in the United 
States in 2002
Rank Bacterial species or group No. of isolates % of total no. of isolates
1 Coagulase-negative staphylocci 34,640 42.0
2 S. aureus 13,618 16.5
3 E. faecalis 6,893 8.3
4 E. coli 5,942 7.2
5 K. pneumoniae 2,942 3.6
6 E. faecium 2,873 3.5
7 Viridans group streptococci 2,773 3.4
8 Pseudomonas aeruginosa 2,030 2.5
9 S. pneumoniae 1,901 2.3
10 Enterobacter cloacae 1,550 1.9
11 Serratia marcescens 814 1.0
12 Acinetobacter baumannii 733 0.9
13 Proteus mirabilis 732 0.9
14 Streptococcus agalactiae 626 0.8
15 Klebsiella oxytoca 470 0.6
16 Enterobacter aerogenes 376 0.5
17 Stenotrophomonas maltophilia 256 0.3
18 Citrobacter freundii 245 0.3
19 Streptococcus pyogenes 211 0.3
20 Enterococcus avium 153 0.2
21 Others 2,791 3.4
Total 82,569 100Annals of Clinical Microbiology and Antimicrobials 2004, 3 http://www.ann-clinmicrob.com/content/3/1/7
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Table 2: In vitro antimicrobial susceptibility testing results for the most common gram-positive and gram-negative bacterial species or 
groups isolated from blood cultures of hospitalized patients in the United States in 2002
Gram-positive bacteria Antimicrobial Total No. % Susceptible
Oxacillin-susceptible CoNSa Amoxicillin-clavulanate 1,692 99.8
Cefotaxime 962 99.7
Ceftriaxone 228 98.7
Cefuroxime 131 100
Ciprofloxacin 1,724 82.1
Clindamycin 2,290 91.2
Erythromycin 2,241 59.2
Gentamicin 1,789 95.7
Levofloxacin 1,652 82.7
Ofloxacin 172 72.7
Penicillin 2,106 31.7
Trimethoprim-sulfamethoxazole 2,099 89.2
Vancomycin 2,273 100
Oxacillin-susceptible S. aureus Amoxicillin-clavulanate 1,854 99.7
Cefotaxime 823 99.6
Ceftriaxone 602 99.8
Cefuroxime 424 99.8
Ciprofloxacin 3,383 88.5
Clindamycin 5,707 93.3
Erythromycin 5,707 69.1
Gentamicin 4,904 97.9
Levofloxacin 3,903 89.4
Ofloxacin 811 84.0
Penicillin 5,532 14.3
Trimethoprim-sulfamethoxazole 4,660 97.8
Vancomycin 5,565 100
E. faecalis Erythromycin 787 13.2
Levofloxacin 1,793 52.1
Penicillin 2,372 97.1
Vancomycin 3,400 95.4
E. faecium Erythromycin 421 4.0
Levofloxacin 758 11.3
Penicillin 913 13.3
Vancomycin 1,285 32.9
Viridans group streptococci Cefotaxime 719 89.2
Ceftriaxone 1,120 89.9
Clindamycin 1,227 89.0
Erythromycin 1,681 46.6
Levofloxacin 661 90.6
Penicillin 2,005 60.0
Vancomycin 1,901 100
S. pneumoniae Amoxicillin-clavulanate 141 97.2
Cefotaxime 750 96.3
Ceftriaxone 1,149 97.2
Cefuroxime 223 70.9
Clindamycin 634 95.1
Erythromycin 1,023 75.2
Levofloxacin 762 99.5
Ofloxacin 196 95.4
Penicillin 1,345 68.0
Trimethoprim-sulfamethoxazole 675 66.8
Vancomycin 1,190 100
Gram-negative bacteria Antimicrobial Total No. % Susceptible
E coli Amikacin 3,815 99.1
Amoxicillin-clavulanate 1,417 79.9
Ampicillin 5,192 52.2Annals of Clinical Microbiology and Antimicrobials 2004, 3 http://www.ann-clinmicrob.com/content/3/1/7
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ceftazidime non-susceptibility, a commonly used pheno-
typic marker for estimating extended-spectrum β-lacta-
mase (ESBL) rates, was 3.8%. For K. pneumoniae, ≥ 90% of
isolates were reported susceptible to amikacin, cefepime,
cefotaxime, ceftriaxone, ciprofloxacin, levofloxacin, and
gentamicin; ceftazidime non-susceptibility was 11.5%.
Among P. aeruginosa, amikacin, piperacillin-tazobactam,
and tobramycin had the highest rates of susceptibility;
however, no agent had susceptibilities ≥ 93%.
The susceptibility of S. aureus to oxacillin from blood cul-
ture isolates also varied by <3% for isolates from inten-
sive-care unit (ICU) patients and non-ICU inpatients. The
ciprofloxacin susceptibility rate for E. coli was similar for
isolates from ICU patients (85.7%) and non-ICU inpa-
tients (86.8%) (Table 3). Similarly, rates of susceptibility
to ceftriaxone among E. coli were similar for isolates from
ICU patients (96.3%) and non-ICU inpatients (97.5%).
Combinations of antimicrobial agents are often pre-
scribed as empiric therapy for suspected or laboratory
confirmed bloodstream infections. Frequently prescribed
combinations include an expanded-spectrum β-lactam or
a fluoroquinolone plus an aminoglycoside for the treat-
ment of infections caused by Gram-negative bacilli while
combinations of an expanded-spectrum β-lactam or a
fluoroquinolone plus vancomycin are often prescribed for
suspected or demonstrated infections caused by Gram-
Cefazolin 5,167 87.5
Cefepime 2,966 98.3
Cefotaxime 2,967 97.7
Ceftazidime 4,067 96.2
Ceftriaxone 3,820 97.3
Cephalothin 1,879 61.5
Ciprofloxacin 4,633 86.7
Gentamicin 5,171 92.8
Levofloxacin 4,266 86.0
Nitrofurantoin 1,356 97.5
Ofloxacin 456 88.6
Piperacillin-tazobactam 3,887 95.4
Tobramycin 4,414 93.5
Trimethoprim-sulfamethoxazole 5,108 74.8
K. pneumoniae Amikacin 1,987 97.6
Amoxicillin-clavulanate 867 86.7
Cefazolin 2,576 86.3
Cefepime 1,613 96.5
Cefotaxime 1,502 93.5
Ceftazidime 2,134 88.5
Ceftriaxone 2,104 93.3
Cephalothin 930 75.3
Ciprofloxacin 2,370 90.3
Gentamicin 2,686 91.1
Levofloxacin 2,264 91.4
Nitrofurantoin 835 55.0
Ofloxacin 275 90.2
Piperacillin-tazobactam 1,997 89.9
Tobramycin 2,320 90.7
Trimethoprim-sulfamethoxazole 2,625 87.2
P. aeruginosa Amikacin 1,563 92.3
Cefepime 1,450 76.7
Ceftazidime 1,764 77.2
Ciprofloxacin 1,734 71.0
Gentamicin 1,858 77.2
Levofloxacin 1,475 68.0
Ofloxacin 199 44.7
Piperacillin-tazobactam 1,484 91.0
Tobramycin 1,708 87.5
aCoNS, coagulase-negative staphylococci
Table 2: In vitro antimicrobial susceptibility testing results for the most common gram-positive and gram-negative bacterial species or 
groups isolated from blood cultures of hospitalized patients in the United States in 2002 (Continued)Annals of Clinical Microbiology and Antimicrobials 2004, 3 http://www.ann-clinmicrob.com/content/3/1/7
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positive pathogens. Beta-lactams or fluoroquinolones are
associated with aminoglycosides. Table 4 depicts the per-
centages of isolates susceptible in vitro to one or both
antimicrobials in 10 combinations of agents tested
against all blood culture isolates reported to TSN Data-
base-USA in 2002. Combining ceftriaxone, ceftazidime,
cefepime, piperacillin-tazobactam or ciprofloxacin with
gentamicin demonstrated consistent susceptibility rates
for each combination (range, 74.8–76.3%). Similarly,
combining ceftriaxone, ceftazdime, cefepime, piperacil-
lin-tazobactam or ciprofloxacin with vancomycin demon-
strated consistent susceptibility rates for each
combination (range, 93.5–96.6%). Combinations includ-
ing gentamicin demonstrated lower rates of susceptibility
by approximately 20% compared with combinations
including vancomycin.
Discussion
S. aureus and E. coli were identified in previous studies as
the two most common blood culture isolates from hospi-
talized patients in the United States and Europe
[4,5,12,13]. In the current study, coagulase-negative sta-
phylococci were the most common blood culture isolates
from laboratories in the United States (42.0% of isolates)
(Table 1). However, given that coagulase-negative staphy-
lococci isolated from blood cultures are often contami-
nants (>85% are clinically insignificant) [5] our results
agree generally with those previously published. As TSN
collects all laboratory data, year-round, it may present a
more accurate description of laboratory testing than do
centralized point prevalence studies that often exclude the
majority of isolates identified by laboratories in a year
[12,13]. Accepting the over-representation of
contaminant coagulase-negative staphylococci in clinical
laboratories in the United States as observed in TSN Data-
base-USA, the rank order of other pathogens is similar to
previous reports describing centralized surveillance
studies [12,13] and hospital review studies [4,5]. Six
organisms, coagulase-negative staphylococci, S. aureus, E.
faecalis, E. coli, K. pneumoniae, and E. faecium accounted
for >80% of blood culture isolates. Previously, SENTRY
has reported similar results for laboratories in the United
States, Canada, Latin America, and Europe [12,13]. In the
current study, overall frequencies of isolation were 78.1%
gram-positive bacteria and 21.9% gram-negative bacteria.
Oxacillin-resistant  S. aureus are extremely important
causes of bloodstream infections and evidence has been
Table 3: In vitro antimicrobial susceptibility of S. aureus to oxacillin and E. coli to ciprofloxacin and ceftriaxone in blood culture isolates 
from ICU and non-ICU inpatients
Organism Antimicrobial agent Inpatient location No. of isolates % of isolates susceptible to antimicrobial agent
S. aureus oxacillin ICU 1,994 48.1
Non-ICU 9,625 51.2
E. coli ciprofloxacin ICU 581 85.7
Non-ICU 4,052 86.8
ceftriaxone ICU 510 96.3
Non-ICU 3,310 97.5
Table 4: In vitro susceptibilities of blood culture isolates from hospitalized patients in the United States in 2002 to antimicrobial 
combinations of a β-lactam or ciprofloxacin plus gentamicin or vancomycin
Antimicrobial Combination Total no. of isolates tested against one or both 
of the antimicrobials in the combination
% of isolates susceptible to at least one 
antimicrobial in the combination
Ceftriaxone + gentamicin 53,648 75.5
Ceftazidime + gentamicin 50,238 76.0
Cefepime + gentamicin 50,489 76.1
Piperacillin-tazobactam + gentamicin 50,415 76.3
Ciprofloxacin + gentamicin 55,973 74.8
Ceftriaxone + vancomycin 62,907 93.5
Ceftazidime + vancomycin 62,518 95.4
Cefepime + vancomycin 59,807 96.6
Piperacillin-tazobactam + vancomycin 61,265 96.3
Ciprofloxacin + vancomycin 64,467 94.1Annals of Clinical Microbiology and Antimicrobials 2004, 3 http://www.ann-clinmicrob.com/content/3/1/7
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presented that oxacillin-resistant S. aureus (Table 3) are
increasing globally among bloodstream isolates and
among isolates from other anatomical sites [12,17]. Fluo-
roquinolone resistance has increased in a consistent step-
wise manner in the United States and Europe for Entero-
bacteriaceae, P. aeruginosa, and S. aureus [12,13,18,19]. It is
important for clinicians to be updated with current data
concerning the susceptibility of commonly prescribed
agents such as the fluoroquinolones and also to be aware
of trends in longitudinal data. The rates of change in
resistance by pathogen and region can help set priorities
for focused intervention efforts.
Early clinical suspicion, rigorous diagnostic measures,
aggressive initiation of appropriate antimicrobial therapy,
comprehensive supportive care, and measures aimed at
reversing predisposing causes (e.g., amelioration of an
underlying disease, removal of foreign bodies, drainage of
abscesses) are the cornerstone of successful management
of patients with sepsis syndrome [5,10]. The selection of
antimicrobials to be used for empiric therapy should be
based on the local rates of susceptibility and on the site of
infection [10]. Early initiation of appropriate antimicro-
bial treatment is critical in decreasing morbidity and mor-
tality among patients with bloodstream infections due to
gram-negative organisms [14]. The initiation of such ther-
apy is almost always empirical, requiring knowledge of
the likely pathogen(s) and their usual antimicrobial sus-
ceptibility patterns [10,20]. Combinations of antimicro-
bial agents are recommended for empiric therapy for
patients with bloodstream infections, particularly for
those patients with the most adverse prognostic factors
[10]. Combination therapy is recommended to cover the
broad range of possible pathogens which may be difficult
to distinguish clinically, because of the possibility of pol-
ymicrobial infections, because they may prevent the emer-
gence of resistance, and because they may have additive or
synergistic antimicrobial activity. For the patient with a
nosocomial bloodstream infection, initial treatment
should consist of an aminoglycoside initially paired with
a broad-spectrum β-lactam. Expanded-spectrum cepha-
losporins are the β-lactam of choice for the non-neutro-
penic patient because of the greater likelihood of Klebsiella
and Staphylococcus infections in these patients [10]. The
regimen of an aminoglycoside paired with a penicillin or
cephalosporin having antipseudomonal activity is pre-
ferred for neutropenic patients, patients with severe
chronic obstructive pulmonary disease or bronchiestatis,
patients receiving assisted ventilation, and patients with
extensive burns [10].
The in vitro potency of ceftriaxone and cefotaxime against
E. coli and  Klebsiella  suggests that single-agent therapy
directed against those bacteria may be successful even in
severely compromised hosts [10]. The superior pharma-
cokinetic and pharmacodynamic properties that exist for
ceftriaxone when compared with cefotaxime may be a
consideration when choosing between these two agents
[18]. In the nosocomial setting, extensive data also con-
firmed the efficacy of ceftriaxone with or without an
aminoglycoside in serious Gram-negative infections,
pneumonia, spontaneous bacterial peritonitis and as sur-
gical prophylaxis [21]. Ceftriaxone, cefotaxime, and
cefepime all have similar indications for pneumonia, skin
and skin structure infections, and urinary tract infections;
however only ceftriaxone and cefotaxime have an indica-
tion for the sepsis syndrome. In the current study, suscep-
tibilities of isolates to one or both agents in combinations
of ceftriaxone, ceftazdime, cefepime, piperacillin-tazo-
bactam or ciprofloxacin plus gentamicin were consistent
(range, 74.8–76.3%) but lower than similar β-lactam or
ciprofloxacin combinations with vancomycin (range,
93.5–96.6%). Ceftazidime, cefepime, imipenem and
meropenem appear most active against P. aeruginosa [10].
Conclusions
In conclusion, susceptibilities to some classes of antimi-
crobials are decreasing, most notably the fluoroquinolo-
nes for Enterobacteriaceae and P. aeruginosa. Many older
antimicrobials including ceftriaxone continue to retain
high rates of susceptibility against many important bacte-
rial pathogens such as those commonly isolated from
blood cultures. Against the most clinically important
gram-positive species including pneumococci, and gram-
negative bacilli such as E. coli (Table 2) susceptibility to
ceftriaxone appears to have changed little, if at all, from
1996 to 2002 [18]. While selective pressure for resistance
through antimicrobial use is important, infection control
practices are critical to limiting the spread of resistant
organisms. The life-threatening nature of bacteremia and
sepsis underscores the importance of using timely surveil-
lance data to develop rational antimicrobial therapy rec-
ommendations and to design strategies to help control
antimicrobial resistance [10,22].
Authors' contributions
JK and MJ conceived the study, provided expert data inter-
pretation and drafted the manuscript. DD analyzed the
study data; CT and DS provided expert microbiological
analysis and interpretation of study data; GV provided
clinical expertise in interpretation of data and drafting
manuscript. All authors read and approved the final
manuscript.
Acknowledgements
The authors would like to thank the participating institutions in TSN® Data-
base-USA, who make data collection possible and Roche Laboratories, Inc., 
who financially supported this study.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Annals of Clinical Microbiology and Antimicrobials 2004, 3 http://www.ann-clinmicrob.com/content/3/1/7
Page 8 of 8
(page number not for citation purposes)
References
1. Diekema DJ, Beekmann SE, Chapin KC, Morel KA, Munson E, Doern
GV: Epidemiology and outcome of nosocomial and commu-
nity-onset bloodstream infection.  J Clin Micro 2003,
41:3655-3660.
2. Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN, Wenzel
RP: Nosocomial bloodstream infections in United States hos-
pitals: a three-year analysis. Clin Infect Dis 1999, 29:239-244.
3. Pittet D, Li N, Woolson RF, Wenzel RP: Microbiological factors
influencing the outcome of nosocomial bloodstream infec-
tions: a 6-year validated, population-based model. Clin Infect
Dis 1997, 24:1068-1078.
4. Weinstein MP, Reller LB, Murray JR, Lichtenstein KA: The clinical
significance of positive blood cultures: a comprehensive anal-
ysis of 500 episodes of bacteremia and fungemia in adults.
Laboratory and epidemiologic observations.  Rev Infect Dis
1983, 5:35-53.
5. Weinstein MP, Towns ML, Quartey SM, Mirrett S, Reimer LG, Parmi-
giani G, Reller LB: The clinical significance of positive blood cul-
tures in the 1990s: a prospective comprehensive evaluation
of the microbiology, epidemiology, and outcome of bactere-
mia and fungemia in adults. Clin Infect Dis 1997, 24:584-602.
6. Wenzel RP, Edmond MB: The impact of hospital-acquired
bloodstream infections. Emerg Infect Dis 2001, 7:174-177.
7. Morbidity and Mortality Weekly Report: Notice to Readers:
CDC's campaign to prevent antimicrobial resistance in
health-care settings. . April 19, 2002
8. National Nosocomial Infections Surveillance (NNIS) System: Noso-
comial infection rates for interhospital comparison: limita-
tions and possible solutions. Infect Control Hosp Epidemiol 1991,
12:609-621.
9. Jarvis WR: The evolving world of healthcare-associated blood-
stream infection surveillance and prevention: is your system
as good as you think?  Infect Control Hosp Epidemiol 2002,
23:236-238.
10. Young LS: Sepsis syndrome. In Principles and Practice of Infectious Dis-
eases 5th edition. Edited by: Mandell GL, Bennett JE, Dolin R. Philadel-
phia: Churchill Livingstone; 2000:806-819. 
11. National Nosocomial Infections Surveillance (NNIS) System:
National Nosocomial Infections Surveillance (NNIS) report,
data summary from October 1986 – April 1997. Am J Infect
Control 1997, 25:477-487.
12. Diekema DJ, Pfaller MA, Jones RN, Doern GV, Kugler KC, Beach ML,
Sader HS, and The SENTRY Participants Group: Trends in antimi-
crobial susceptibility of bacterial pathogens isolated from
patients with bloodstream infections in the USA, Canada
and Latin America. Int J Antimicrob Agents 2000, 13:257-271.
13. Fluit AC, Jones ME, Schmitz FJ, Acar J, Gupta R, Verhoef J, and the
SENTRY Participants Group: Antimicrobial susceptibility and
frequency of occurrence of clinical blood isolates in Europe
from the SENTRY Antimicrobial Surveillance Program,
1997 and 1998. Clin Infect Dis 2000, 30:454-460.
14. Diekema DJ, Pfaller MA, Jones RN, Doern GV, Winokur PL, Gales
AC, Sader HS, Kugler K, Beach M: Survey of bloodstream infec-
tions due to gram-negative bacilli: frequency of occurrence
and antimicrobial susceptibility of isolates collected in the
United States, Canada, and Latin America for the SENTRY
antimicrobial surveillance program, 1997. Clin Infect Dis 1999,
29:595-607.
15. Sahm DF, Marsilio MK, Piazza G: Antimicrobial resistance in key
bloodstream bacterial isolates: electronic surveillance with
the surveillance network database – USA. Clin Infect Dis 1999,
29:259-263.
16. National Committee for Clinical Laboratory Standards: Perform-
ance standards for antimicrobial susceptibility testing; tenth
informational supplement. National Committee for Clinical Labora-
tory Standards, Wayne, PA 2002:M100-S12.
17. Diekema DJ, Pfaller MA, Schmitz FJ, Smayevsky J, Bell J, Jones RN,
Beach M, and the SENTRY Participants Group: Survey of infections
due to Staphylococcus species: frequency of occurrence and
antimicrobial susceptibility of isolates collected in the
United States, Canada, Latin America, Europe and the
Western Pacific region for the SENTRY antimicrobial sur-
veillance program, 1997–1999. Clin Infect Dis 2001, 32:S114-S132.
18. Karlowsky JA, Jones ME, Mayfield DC, Thornsberry C, Sahm DF:
Ceftriaxone activity against Gram-positive and Gram-nega-
tive pathogens isolated in US clinical microbiology laborato-
ries from 1996 to 2000: results from The Surveillance
Network®(TSN®) Database-USA. Int J Antimicrob Agents 2002,
19:413-426.
19. Livermore DM, James D, Reacher M, Graham C, Nichols T, Stephens
P, Johnson AP, George RC: Trends in fluoroquinolone (cipro-
floxacin) resistance in Enterobacteriaceae from bactere-
mias, England and Wales, 1990–1999. Emerg Infect Dis 2002,
8:473-478.
20. Munson EL, Diekema DJ, Beekmann SE, Chapin KC, Doern GV:
Detection and treatment of bloodstream infection: labora-
tory reporting and antimicrobial management. J Clin Microbiol
2003, 41:495-497.
21. Lamb HM, Ormrod D, Scott LJ, Figgitt DP: Ceftriaxone an update
of its use in the management of community-acquired and
nosocomial infections. Drugs 2002, 62:1041-1089.
22. Decousser JW, Pina P, Picot F, Delalande C, Pangon B, Courvalin P,
Allouch P, and the ColBVH Study Group: Frequency of isolation
and antimicrobial susceptibility of bacterial pathogens iso-
lated from patients with bloodstream infections: a French
prospective national survey.  J Antimicrob Chem 2003,
51:1213-1222.